Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.
In response to a devastating group B meningococcal disease epidemic in New Zealand, a case was prepared for new health funding and a new outer membrane vesicle vaccine, MeNZB, developed. Following clinical trials demonstrating satisfactory immunogenicity and safety profiles a national implementation strategy was prepared. MeNZB was introduced halfway through the 14th year of the epidemic with a campaign targeting children and young people aged under 20 years delivered over 2 years. By its completion in June 2006, the vaccine had been delivered to more than 1 million young people. All of the above steps were achieved within 5 years. This unique endeavour was possible due to a private/public partnership between the New Zealand Ministry of Health and Chiron Vaccines. This paper summarises the outcomes of this campaign including coverage levels achieved, evidence of vaccine effectiveness and safety, and the strategies used to manage key events and risks that emerged during the campaign.
O'Hallahan
Jane
J
Ministry of Health, Wellington, New Zealand. Jane_OHallahan@moh.govt.nz
McNicholas
Anne
A
Galloway
Yvonne
Y
O'Leary
Eileen
E
Roseveare
Christine
C